PRESS RELEASES

Apposition III Results

STENTYS expands its product offerings

STENTYS Self-Apposing technology supported by breaking new scientific evidence

Increased reimbursement of Self-Expanding drug-eluting stents in Germany now for all indications

STENTYS concludes clinical trial ahead of plan

Outstanding interim results of STENTYS international clinical study APPOSITION III

STENTYS Self-Apposing Stents in “perfect apposition to vessels” after treating patients with heart attacks

STENTYS completes enrollment of APPOSITION III study

Over 1000 patients have benefited from STENTYS Self-Apposing technology

2011 Half-Year results

Revenues for the 1st half of 2011

Prof. Gilles Montalescot joins STENTYS Scientific Advisory Board

STENTYS recruits Country managers for France and Italy

STENTYS joins Stent for Life Initiative

Stenting in STEMI: Does Size Matter?

STENTYS enrolls first 250 patients within the framework of its Apposition III international study

STENTYS expands operations into four additional European countries

Increased reimbursement of STENTYS drug-eluting stent in Germany

STENTYS begins large-scale, “real life” study with its selfapposing stent for treatment of Heart Attacks

50 patients already enrolled

STENTYS appoints Mr Michel Darnaud to its Board of Directors

APPOSITION II clinical trial results

STENTYS self-apposing stent proves superior to conventional treatment of Acute Myocardial Infarction

STENTYS completes enrollment in clinical study of its breakthrough stent to treat Acute Myocardial Infarction.

STENTYS appoints Stanislas Piot as Chief Financial Officer

STENTYS drug-eluting self-expanding stent receives CE Marking.

STENTYS self-expanding stent receives CE Marking to treat acute coronary syndrome (ACS).

STENTYS drug-eluting self-expanding coronary stent shows 4% restenosis in complex lesions.

First patient enrolled in randomized study of STENTYS self-expanding stent vs. conventional stent to treat acute myocardial infarction (AMI).

STENTYS expands Scientific Advisory Board (SAB) on heels of reporting successful clinical trial results for world’s first self-expanding stent to treat AMI.

STENTYS discloses results for world’s first clinical study to treat acute myocardial infarction (AMI) with a self-expanding stent.